Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Valensi, P.
Right arrow Articles by Slama, G.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Sulphonylureas and cardiovascular risk: facts and controversies

Paul Valensi

Department of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, AP-HP, Paris-Nord University, Bondy-France, paul.valensi{at}jvr.aphp.fr

Gérard Slama

Diabetology Department, Hotel-Dieu Hospital, 1 place du Parvis Notre-Dame, Paris 75004, France

Cardiovascular complications are the principal cause of death in type 2 diabetes. The importance of glycaemic control in preventing cardiovascular complications has been demonstrated. However, some oral antidiabetic agents and especially some sulphonylureas (SU) have been accused of having a deleterious effect on cardiovascular risk. A retrospective analysis of the administrative database of Saskatchewan Health for 5,795 subjects, identified by their first-ever dispensation for an oral antidiabetic agent, suggests that a higher exposure to SUs was associated with increased mortality. Nevertheless, the effects of SUs on cardiac ATP-sensitive potassium channels in experimental studies vary between agents and studies, so that the clinical relevance of this phenomenon is unclear. Moreover, 11 years of follow-up of patients randomised to glibenclamide or chlorpropamide in the United Kingdom Prospective Diabetes Study demonstrated no adverse effects on a range of cardiovascular end points. Despite SU structural differences and differences in binding to cardiac SU receptors, the clinical evidence base does not support the selection of one sulphonylurea over another on the basis of ischaemic preconditioning, possibly because ischaemic preconditioning may be blunted or absent in diabetes. The main objective remains the prevention or delay of diabetic complications through improvement of glycaemic control together with other cardiovascular risk factors.

Key Words: sulphonylurea • type 2 diabetes • oral antidiabetic agent • myocardial ischaemia • glibenclamide • gliclazide.

References

  • Mensah GA, Mokdad AH, Ford E. et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004;22:485-504.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Backer G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(suppl 1):S1-S78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. Available at www.idf.org
  • Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.[Abstract/Free Full Text]
  • Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.[Abstract/Free Full Text]
  • Goldner MG, Knatterud GL, Prout TE Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-10.[Abstract/Free Full Text]
  • Selzer HS A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Feinglos MN, Bethel MA Therapy of type 2 diabetes, cardiovascular death and the UGDP. Am Heart J 1999;138:S346-S52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-15.[Abstract/Free Full Text]
  • Malmberg K., Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61.[Abstract/Free Full Text]
  • Hirsch IB Were we wrong about insulin and acute myocardial infarction? DOC News 2004;1:4-5.[Free Full Text]
  • Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174: 169-74.[Abstract/Free Full Text]
  • Granberry MC, Fonseca VA Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005;5:201-09.[CrossRef][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Charbonnel B., Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 2004;27:1647-53.[Abstract/Free Full Text]
  • Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guillausseau PJ Hyperglycémie et hypoglycémiants: risques vasculaires. Réal Cardiol 2005;207:39-42.
  • Bailey CJ Oral antidiabetic drugs in Encyclopedic Reference of Molecular Pharmacology 2004. Offerman S, Rosenthal W (eds). Springer-Verlag, Heidelberg 2004;688-95.
  • Ashcroft FM, Gribble FM ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.secretion:[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gribble FM, Ashcroft FM Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide. Diabetologia 1999;42:845-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Downey JM An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning. Cardiovasc Res 1993;27:1565.[Free Full Text]
  • Gross GJ Auchampach JA Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.[Abstract/Free Full Text]
  • Ishihara M., Inoue I., Kawagoe T. et al. Diabetes mellitus prevents ischaemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001;38:1007-11.[Abstract/Free Full Text]
  • Ghosh S., Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001;37:711-18.[Abstract/Free Full Text]
  • Lee TM, Chou TF Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-7.[Abstract/Free Full Text]
  • Gaines KL, Hamilton S., Boyd AE 3rd. Characterisation of the sulfonylurea receptor on beta cell membranes. J Biol Chem 1988;263:2589-92.[Abstract/Free Full Text]
  • Riveline JP, Danchin N., Ledru F., Varroud-Vial M., Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003;29:207-22.[Web of Science][Medline] [Order article via Infotrieve]
  • Samaha FF, Heineman FW, Ince C., Fleming J., Balaban RS ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol 1992;262:C1220-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Cyrys S., Daut J. The sensitivity of coronary vascular tone to glibenclamide: a study on the isolated perfused guinea pig heart. Cardiovasc Res 1994;28:888-93.[Abstract/Free Full Text]
  • Munch-Ellingsen J., Bugge E., Ytrehus K. Blockade of the KATP-channel by glibenclamide aggravates ischaemic injury, and counteracts ischaemic preconditioning. Basic Res Cardiol 1996;91:382-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Mei DA, Gross GJ Evidence for the involvement of the ATP-sensitive potassium channel in a novel model of hypoxic preconditioning in dogs. Cardiovasc Res 1995;30:222-30.[Abstract/Free Full Text]
  • Qian YZ, Levasseur JE, Yoshida K., Kukreja RC KATP channels in rat heart: blockade of ischaemic and acetylcholine-mediated preconditioning by glibenclamide. Am J Physiol 1996;271(1 Pt 2):H23-H28.[Web of Science][Medline] [Order article via Infotrieve]
  • Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J. Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels. Cardiovasc Res 1993;27:623-9.[Abstract/Free Full Text]
  • Toombs CF, Moore TL, Shebuski RJ Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993;27:617-22.[Abstract/Free Full Text]
  • Miura T., Goto M., Miki T., Sakamoto J., Shimamoto K., Iimura O. Glibenclamide, a blocker of ATP-sensitive potassium channels, abolishes infarct size limitation by preconditioning in rabbits anesthetized with xylazine/pentobarbital but not with pentobarbital alone. J Cardiovasc Pharmacol 1995;25:531-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Fralix TA, Steenbergen C., London RE, Murphy E. Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart. Cardiovasc Res 1993;27:630-7.[Abstract/Free Full Text]
  • Jerome SN, Akimitsu T., Gute DC, Korthuis RJ Ischaemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol 1995;268:H2063-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Wilde AA Role of ATP-sensitive K+ channel current in ischaemic arrhythmias. Cardiovasc Drugs Ther 1993:7(suppl 3):521-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pogatsa G. What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents? Diabetes Res Clin Pract 1996;31 (suppl):S27-S31.[CrossRef][Medline] [Order article via Infotrieve]
  • D'Alonzo AJ, Darbenzio RB, Hess TA, Sewter JC, Sleph PG, Grover GJ Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res 1994;28:881-7.[Abstract/Free Full Text]
  • Baczko I., Lepran I., Papp JG KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Eur J Pharmacol 1997;324:77-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vegh A., Papp JG, Szekeres L., Parratt JR Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc Res 1993;27:638-43.[Abstract/Free Full Text]
  • Maddock HL, Siedlecka SM, Yellon DM Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004;18:113-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ballagi-Pordany G., Koszeghy A., Koltai MZ, Aranyi Z., Pogatsa G. Divergent cardiac effects of the first and second generation hypoglycaemic sulfonylurea compounds. Diabetes Res Clin Pract 1990;8:109-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischaemic preconditioning or diazoxide. Circulation 2001;103:3111-16.[Abstract/Free Full Text]
  • Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-46.[Abstract/Free Full Text]
  • Horimoto H., Nakai Y., Mieno S., Nomura Y., Nakahara K., Sasaki S. Oral hypoglycaemic sulfonylurea glimepiride preserves the myoprotective effects of ischaemic preconditioning. J Surg Res 2002;105:181-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • El-Reyani NE, Baczko I., Lepran I., Papp JG Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol 1999;365:187-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S. et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002;51:808-12.[Abstract/Free Full Text]
  • St John Sutton M., Rendell M., Dandona P. et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64.[Abstract/Free Full Text]
  • Lee TM, Su SF, Chou TF, Lee YT, Tsai CH Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334-40.[Abstract/Free Full Text]
  • Larsen JJ, Dela F., Madsbad S., Vibe-Petersen J., Galbo H. Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care 1999;22:1647-54.[Abstract/Free Full Text]
  • Tomai F., Danesi A., Ghini AS et al. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J 1999;20:196-202.[Abstract/Free Full Text]
  • Ovunc K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000;23:535-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Ferreira BM, Moffa PJ, Falcao A. et al. The effects of glibenclamide, a K(ATP) channel blocker, on the warm-up phenomenon. Ann Noninvasive Electrocardiol 2005;10:356-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Correa SD, Schaefer S. Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol 1997;79:75-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bogaty P., Kingma JG Jr, Robitaille NM et al. Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina: relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel. J Am Coll Cardiol 1998; 32:1665-71.[Abstract/Free Full Text]
  • Lindhardt TB, Abedini S., Olesen RM, Haunso S., Gadsboll N. Effects of Pharmacological Modulation of the ATP-Sensitive Potassium Channels on the Development of Warm-Up Angina Pectoris. Cardiology 2005;15: 17-21.[CrossRef]
  • Rana JS, Mukamal KJ, Nesto RW, Morgan JP, Muller JE, Mittleman MA Effect of diabetes mellitus and its treatment on ventricular arrhythmias complicating acute myocardial infarction. Diabet Med 2005;22:576-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tentolouris N., Matsagura M., Psallas M. et al. Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin. Exp Clin Endocrinol Diabetes 2005;113:298-301.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Markham A., Plosker GL, Goa KL Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60:955-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Geshi E., Ishioka H., Nomizo A., Nakatani M., Katagiri T. The role of ATPsensitive potassium channels in the mechanism of ischaemic preconditioning. J Cardiovasc Pharmacol 1999;34:446-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hata N., Takano M., Kunimi T., Kishida H., Takano T. Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris. Int J Clin Pharmacol Res 2001;21:59-63.[Web of Science][Medline] [Order article via Infotrieve]
  • Danchin N., Charpentier G., Ledru F. et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005;21: 143-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Klamann A., Sarfert P., Launhardt V., Schulte G., Schmiegel WH, Nauck MA Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000;21:220-9.[Abstract/Free Full Text]
  • Halkin A., Roth A., Jonas M., Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001;12:177-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 1. Weih M., Amberger N., Wegener S., Dirnagl U., Reuter T., Einhaupl K. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 2001;32:2029-32.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 4, 159-165 (2006)
DOI: 10.1177/14746514060060040301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Valensi, P.
Right arrow Articles by Slama, G.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?